Rebecka Ventin-Holmberg

Mrs. Rebecka Ventin-Holmberg

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2022 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
RVRebecka Ventin-Holmberg
Rebecka Ventin-Holmberg
SSSchahzad Saqib
Schahzad Saqib
KKKatri Korpela
Katri Korpela
ANAnne Nikkonen
Anne Nikkonen
VPVille Peltola
Ville Peltola
KKKaija-Leena Kolho
Kaija-Leena Kolho
Antibiotics are commonly used drugs in infants, causing disruptions in the developing gut microbiota with possible detrimental long-term effects such as chronic inflammatory diseases. The focus has been on bacteria, but research shows that fungi might have an important role as well. There are only a few studies on the infant gut fungal microbiota, the mycobiota, in relation to antibiotic treatment. Here, the aim was to investigate the impact of antibiotics on the infant gut mycobiota, and the interkingdom associations between bacteria and fungi. We had 37 antibiotic-naïve patients suffering from respiratory syncytial virus, of which 21 received one to four courses of antibiotics due to complications, and 16 remained antibiotic-naïve throughout the study. Fecal samples were collected before, during and after antibiotic treatment with a follow-up period of up to 9.5 months. The gut mycobiota was studied by Illumina MiSeq sequencing of the ITS1 region. We found that antibiotic use affected the gut mycobiota, most prominently seen as a higher relative abundance of Candida (p < 0.001), and a higher fungal diversity (p = 0.005–0.04) and richness (p = 0.03) in the antibiotic-treated infants compared to the antibiotic-naïve ones at multiple timepoints. This indicates that the gut mycobiota could contribute to the long-term consequences of antibiotic treatments.

5 August 2025 in Microbiology Spectrum
Verified
Journal Article
Open access
RVRebecka Ventin-Holmberg
Rebecka Ventin-Holmberg
JEJulia Eriksson
Julia Eriksson
AEAnja Eberl
Anja Eberl
TSTaina Sipponen
Taina Sipponen
ENEija Nissilä
Eija Nissilä
PSPäivi Saavalainen
Päivi Saavalainen
Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic inflammatory gastrointestinal disorders linked to genetic predisposition and environmental factors. The gut microbiota, composed of various microorganisms, plays a crucial role in IBD, as reduced anaerobic bacteria and short-chain fatty acid (SCFA) producers are associated with predisposition to IBD. There is no cure for IBD, but the treatment aims for mucosal healing including conventional treatment and biological therapies such as infliximab (IFX). IFX, a tumor necrosis factor alpha (TNF-α) blocker, effectively reduces inflammation, but around 50% of patients do not achieve long-term remission. Fecal samples were collected from 70 patients with IBD (24 CD, 44 UC, and 2 IBDU), and mucosal samples were collected from both ileum and colon from 63 patients before, during, and after IFX treatment. The bacterial microbiota composition was investigated by targeting the conserved 16S region in MiSeq sequencing. Additionally, the relative sequencing data were quantified by qPCR. Responders to IFX had an increase in the total bacterial load in ileum and fecal samples during treatment, primarily driven by butyrate-producing bacteria in the Firmicutes phylum. Interestingly, this was only observed in the fecal samples in responders, but not non-responders to IFX. These results indicate that the gut bacterial microbiota of responders to IFX is changing toward a more favorable composition during successful IFX treatment. IMPORTANCE: The research described in this paper enhances our understanding of how infliximab (IFX) treatment affects the gut mucosal and fecal microbiota in patients with inflammatory bowel disease (IBD). Using 16S sequencing technique and quantification by qPCR, the study revealed that successful treatment with IFX led to an increase in the total bacterial load in both ileal and fecal samples, as well as a shift in bacterial composition toward a more favorable profile with an increase in butyrate-producing bacteria in the fecal samples in responders but not in non-responders to infliximab. This study emphasizes that the gut microbiota plays an important role in the healing process during infliximab treatment in IBD.

9 September 2026 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
PDF file
HKHelka Kaunisto
Helka Kaunisto
EKEsko Kemppainen
Esko Kemppainen
TSTeea Salmi
Teea Salmi
KLKatarzyna Leskinen
Katarzyna Leskinen
HPHeli Pessa
Heli Pessa
KLKatri Lindfors
Katri Lindfors
Dermatitis herpetiformis (DH) is a dietary gluten -induced autoimmune blistering skin disease. It is hypothesized to be initiated by a small intestinal mucosal immune response. Gluten-free diet (GFD) is the primary treatment for DHdermatitis herpetiformis and effectively resolves skin lesions. Previous studies show that after gluten reintroduction, peripheral cell responses are detectable already in six6 days, and most patients relapse clinically within months. The relapse presentation may differ between patients, with some experiencing both rash and small intestinal mucosal damage and some only one of these. Here, RNA transcriptomics were utilized to characterize temporal systemic and small intestinal mucosal responses to gluten in DH,dermatitis herpetiformis and to identify transcriptomic profiles specific for rash or villous atrophy as relapse presentations. The cohort consisted of 19 DHdermatitis herpetiformis patients on GFDgluten-free diet who underwent a gluten challenge. Gluten challenge elicited pronounced gene expression changes related to inflammation in the small intestine. In patients relapsing with rash, DOCK8 expression was significantly upregulated, while IL10RB was downregulated at end of follow-up. These patients also had significantly increased frequency of intraepithelial lymphocytes. Our findings show that prolonged gluten exposure alters duodenal transcriptomic profiles considerably. Moreover, patterns related to rash could be detected and present interesting candidates for future studies.

22 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
MIMaria A. Ilomäki
Maria A. Ilomäki
EKEkta Kotharkar
Ekta Kotharkar
JRJannika Rovapalo
Jannika Rovapalo
NLNoora Lehtonen
Noora Lehtonen
ANAnne Nikkonen
Anne Nikkonen
DTDiana Toivola
Diana Toivola
Background: Inflammatory bowel disease (IBD) is associated with early structural changes in intestinal epithelial cells; however, the associated molecular alterations remain incompletely understood. The cytoskeletal protein keratin (K) 7 was recently found to be focally expressed in the colonic epithelium in IBD, while absent in the healthy colon. Here, we investigated the applicability of K7 as a noninvasive stool biomarker for pediatric IBD. Methods: In this case-control study including adolescent patients with IBD (n=27) and healthy controls (n=15), stool lysates were analyzed by proteomics, immunoassay and qPCR to determine K7 protein and mRNA content, respectively. Additionally, stool mRNA levels of the simple epithelial keratins, K8, K18, K19 and K20, were measured. Results: Stool proteomic analysis identified focal K7 and K19 in IBD samples. Additionally, 23 differentially abundant proteins, of which 18 were higher in IBD, were identified and Gene Ontology enrichment analysis highlighted immune and inflammatory pathways. K7 specific immunoassay detected fecal K7 protein in all patients with active IBD, including both ulcerative colitis and Crohn’s disease, while K7 was near or below the detection limit in controls and IBD patients in remission (area under ROC curve=0.88, p<0.0001). While KRT7 mRNA levels were below the detection limit, KRT8 and KRT18 transcripts were elevated in IBD samples compared to controls (p<0.05). Conclusions: K7 protein is elevated in IBD patient stool, reflecting intestinal de novo expression and increased epithelial cell exfoliation. Fecal K7 may provide a novel, noninvasive marker for IBD diagnosis and monitoring.